Waters Corporation (WATERS CORP) - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended October 1, 2005. Waters Corporation designs, manufactures, and services analytical instrument systems, including high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), and mass spectrometry (MS) instruments, as well as thermal analysis and rheometry instruments. The company operates through two primary divisions: Waters Division and TA Instruments Division.
Key Financial Metrics
(All figures in thousands, except per share data)
| Metric | Three Months Ended Oct 1, 2005 | Nine Months Ended Oct 1, 2005 |
|---|---|---|
| Total Net Sales | $273,031 | $825,966 |
| Gross Profit | $157,523 | $481,591 |
| Operating Income | $62,655 | $187,487 |
| Net Income | $25,717 | $126,377 |
| Diluted EPS | $0.22 | $1.07 |
| Cash from Operations (9mo) | $238,996 | |
| Cash and Equivalents (Oct 1, 2005) | $488,903 | |
| Total Debt (Current + Long-term) | $653,791 |
Margins: Gross margin for the quarter was 57.7% (down from 58.1% in the prior year quarter). Operating margin was 22.9%.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 3% for the quarter and 6% for the nine-month period compared to the prior year. Growth was driven by strong demand in Asia and Japan, offset by weakness in U.S. and European instrument sales due to delayed capital budgets from pharmaceutical customers.
- Profitability Decline: Net income decreased significantly year-over-year ($25.7M vs. $51.9M for the quarter). This decline is primarily attributed to a $24.0 million one-time tax provision related to the repatriation of foreign earnings under the American Jobs Creation Act (AJCA).
- Debt Increase: Total borrowings increased to $635.0 million (up from $440.0 million at year-end 2004) to fund an aggressive stock repurchase program. Interest expense rose to $6.6 million for the quarter from $2.6 million.
- Product Mix: LC sales grew 5% in constant currencies, while MS sales declined 4% due to weaker demand for quadrupole systems. Laboratory Informatics sales remained below management expectations.
Guidance, Outlook, and Risks
- Outlook: Management expects pharmaceutical spending to remain weak until capital budgets are released. However, industrial spending trends (TA Division) are anticipated to remain favorable.
- Share Repurchases: The company completed a $500 million stock repurchase program in the quarter, buying back 4.3 million shares. On October 24, 2005, the Board authorized a new $500 million repurchase program over two years.
- Tax Repatriation: The company recorded a $24.0 million tax liability for repatriating $500 million in foreign cash. Payments of $19.0 million are expected in Q4 2005 and Q1 2006.
- Accounting Changes: The company will adopt SFAS 123(R) regarding share-based payments in the first quarter of 2006, which is expected to have a material impact on reported earnings.
- Litigation: Ongoing patent litigation with Hewlett-Packard/Agilent remains a contingency. A provision of $2.9 million is accrued for potential damages in England and France suits. The company recently won a non-infringement ruling in the UK appellate court.
Investor Verification Checklist
- Tax Impact: Verify the timing and cash outflow of the $19.0 million tax payment related to the AJCA repatriation in Q4 2005/Q1 2006.
- Pharma Spending: Monitor the release of capital budgets from large pharmaceutical customers, which is the primary driver of the current sales weakness in the U.S. and Europe.
- Debt Covenants: Confirm continued compliance with the amended Credit Agreement leverage ratio (increased to 3.25:1) given the increased debt load from share buybacks.
- MS Product Demand: Assess the recovery of Mass Spectrometry sales, which declined 4% in the quarter due to competitive pressures and reduced pharma spending.
- Stock Buyback Execution: Track the utilization of the newly authorized $500 million share repurchase program.